CircAKR1B10 interacts with EIF4A3 to stabilize AURKA and promotes IL-22-induced proliferation, migration and invasion in keratinocytes
- PMID: 39177716
- DOI: 10.1007/s00403-024-03302-8
CircAKR1B10 interacts with EIF4A3 to stabilize AURKA and promotes IL-22-induced proliferation, migration and invasion in keratinocytes
Abstract
Circular RNAs (circRNAs) are demonstrated to be involved in psoriasis progression. CircRNAs can act as RNA-binding protein (RBP) sponges. Here, we investigated the action of circAKR1B10 in psoriasis, and explored the potential proteins interacted with circAKR1B10. Levels of genes and proteins were assayed by qRT-PCR and western blotting analyses. Keratinocytes in functional groups were treated with interleukin (IL)-22. Functional analysis were conducted using MTT, 5-ethynyl-2'-deoxyuridine (EdU), and transwell assays, respectively. Interaction analysis among circAKR1B10, Eukaryotic initiation factor 4 A-III (EIF4A3) and Aurora Kinase A (AURKA) was conducted using bioinformatics analysis, RNA pull-down assay, and RNA immunoprecipitation (RIP) assay. CircAKR1B10 was highly expressed in psoriasis patients and IL-22-induced keratinocytes. Functionally, knockdown of circAKR1B10 abolished IL-22-induced proliferation, migration and invasion in keratinocytes. AURKA expression was also higher in psoriasis patients and IL-22-induced keratinocytes, and was negatively correlated with circAKR1B10 expression. Moreover, AURKA silencing reduced the proliferative, migratory and invasive abilities of IL-22-induced keratinocytes. Mechanistically, circAKR1B10 interacted with EIF4A3 protein to stabilize and regulate AURKA expression. CircAKR1B10 contributes to IL-22-induced proliferation, migration and invasion in keratinocytes via up-regulating AURKA expression through interacting with EIF4A3 protein.
Keywords: AURKA; EIF4A3; IL-22; Keratinocytes; Psoriasis; circAKR1B10.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J, Psoriasis (2021) Lancet 397(10281):1301–1315. https://doi.org/10.1016/s0140-6736(20)32549-6 - DOI - PubMed
-
- Wei L, Chen S, Zhang Z et al (2022) Prevalence of Tobacco Smoking and its Association with Disease Severity among patients with psoriasis in China: a cross-sectional study. Front Med (Lausanne) 9(883458). https://doi.org/10.3389/fmed.2022.883458
-
- Kaplon H, Chenoweth A, Crescioli S, Reichert JM (2022) Antibodies to watch in 2022. MAbs 14(1):2014296. https://doi.org/10.1080/19420862.2021.2014296 - DOI - PubMed - PMC
-
- Dave R, Alkeswani A (2021) An overview of Biologics for Psoriasis. J Drugs Dermatol 20(11):1246–1247. https://doi.org/10.36849/jdd.6040 - DOI - PubMed
-
- Zhou X, Chen Y, Cui L, Shi Y, Guo C (2022) Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis 13(1):81. https://doi.org/10.1038/s41419-022-04523-3 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous
